Clinical trials: Decompensated Cirrhosis
Liver Cirrhosis
Observational Prospective Study.at the End of the Study the Patients Will be Classified According to PH,Serum Bicarbonate and Serum Sodium Into 6 Groups and Statistical Analysis Will be Performed Using Spss
1-to identify the prognostic value of serum bicarbonate and serum electrolytes at time of admission and their association with development of complications ,length of hospital stay ,prognosis and mortality in hospitalized…
- Trial name
- NCT05082064
- Testing
- arterial blood gases and serum electrolytes
- Where
- Egypt
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Sohag University
Exocrine Pancreatic Insufficiency
Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to perform a normal digestive function. The prevalence of IPE in patients with decompensated hepatic cirrhosis (HC) is unknown and most published series are…
- Trial name
- (EPIIHC) (NCT03236038)
- Testing
- Labeled triolein urea breath test
- Where
- Spain
- Volunteers
- 125 people
- Sponsor
- Corporacion Parc Tauli
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Cirrhosis
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease.
- Trial name
- NCT07652203
- Testing
- conventional therapy, propranolol
- Where
- China
- Volunteers
- 466 people
- Sponsor
- General Hospital of Shenyang Military Region
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)
This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis.
- Trial name
- NCT05984303
- Testing
- Human Umbilical Cord-derived Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing 302 Hospital
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Liver Cirrhosis With Acute Decompensation
Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures
Patients with liver cirrhosis have historically received prophylactic transfusions before invasive procedures with high risk of bleeding.
- Trial name
- PROTECT-CIRR (NCT07437755)
- Testing
- Blood Products transfusion
- Where
- Romania
- Volunteers
- 116 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Decompensated Cirrhosis and Ascites
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants…
- Trial name
- PRECIOSA (NCT03451292)
- Testing
- Albutein 20%, SMT
- Where
- 66 sites in United States, Belgium and 12 more
- Volunteers
- 410 people
- Sponsor
- Grifols Therapeutics LLC
Hepatitis B Virus, Decompensated Cirrhosis
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.
- Trial name
- NCT00663182
- Testing
- Entecavir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Acute Kidney Injury, Cirrhosis
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital.
- Conditions
- Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
- Trial name
- DROP-AKI (NCT06937307)
- Testing
- Droxidopa capsules
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Giuseppe Cullaro, MD
Cirrhosis
Rifaximin Predicts the Complications of Decompensated Cirrhosis
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02074280
- Testing
- rifaximin
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Changzheng Hospital
Liver Cirrhosis
Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis
Patients with decompensated liver cirrhosis exhibit numerous hemodynamic and microvascular changes, i.e., low systemic blood pressure and peripheral vasodilatation.
- Trial name
- NCT00849641
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- University of Regensburg
Decompensated Cirrhosis
Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
The current prospective randomized controlled trial would aim to study the efficacy of targeted albumin therapy versus standard medical treatment in reduction in 6-month mortality in recurrent ascites in patients with…
- Trial name
- NCT04679571
- Testing
- Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02190357
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Spontaneous Bacterial Peritonitis
Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis
Spontaneous bacterial peritonitis is defined as the presence of an infection in a previously sterile ascites in the absence of an intra-abdominal source of infection or malignancy .
- Trial name
- NCT03163745
- Testing
- paracentesis
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Decompensated Cirrhosis, Bleeding Varices
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced…
- Trial name
- NCT01370161
- Testing
- TIPS treatment, Medical treatment
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Air Force Military Medical University, China
Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in asymptomatic individuals.
- Trial name
- SIBOC (NCT04775329)
- Testing
- Rifaximin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Changi General Hospital
NASH Related Decompensated Cirrhosis
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
The study will be conducted in the Department of Hepatology, Institute of Liver \& Biliary Sciences, New Delhi. As a part of this study history will be taken and clinical examination will be done.
- Trial name
- NCT02868164
- Testing
- Fecal Microbiota Transplantation, Standard Treatment, Weight Reduction
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India